Mondrian Investment Partners LTD Purchases 506,752 Shares of Dr. Reddy’s Laboratories Limited (NYSE:RDY)

Mondrian Investment Partners LTD boosted its position in Dr. Reddy’s Laboratories Limited (NYSE:RDY) by 356.7% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 648,813 shares of the company’s stock after acquiring an additional 506,752 shares during the quarter. Mondrian Investment Partners LTD’s holdings in Dr. Reddy’s Laboratories were worth $10,245,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Robeco Institutional Asset Management B.V. increased its holdings in Dr. Reddy’s Laboratories by 453.8% during the 4th quarter. Robeco Institutional Asset Management B.V. now owns 11,438,908 shares of the company’s stock worth $180,620,000 after purchasing an additional 9,373,412 shares in the last quarter. Fisher Asset Management LLC increased its holdings in Dr. Reddy’s Laboratories by 402.5% during the 4th quarter. Fisher Asset Management LLC now owns 2,468,722 shares of the company’s stock worth $38,981,000 after purchasing an additional 1,977,419 shares in the last quarter. Allspring Global Investments Holdings LLC increased its holdings in Dr. Reddy’s Laboratories by 400.6% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 534,304 shares of the company’s stock worth $8,373,000 after purchasing an additional 427,573 shares in the last quarter. Rhumbline Advisers increased its holdings in Dr. Reddy’s Laboratories by 458.0% during the 4th quarter. Rhumbline Advisers now owns 430,062 shares of the company’s stock worth $6,791,000 after purchasing an additional 352,994 shares in the last quarter. Finally, Vestcor Inc increased its holdings in Dr. Reddy’s Laboratories by 350.7% during the 4th quarter. Vestcor Inc now owns 381,670 shares of the company’s stock worth $6,027,000 after purchasing an additional 296,993 shares in the last quarter. 3.85% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts have commented on RDY shares. Nomura lowered Dr. Reddy’s Laboratories from a “buy” rating to a “neutral” rating in a report on Thursday, December 19th. StockNews.com lowered Dr. Reddy’s Laboratories from a “buy” rating to a “hold” rating in a report on Friday, December 6th.

Dr. Reddy’s Laboratories Price Performance

Shares of NYSE RDY opened at $12.64 on Friday. Dr. Reddy’s Laboratories Limited has a twelve month low of $12.50 and a twelve month high of $16.89. The stock’s 50 day moving average price is $13.99 and its 200-day moving average price is $14.86. The company has a market capitalization of $10.55 billion, a PE ratio of 20.12 and a beta of 0.48. The company has a quick ratio of 1.38, a current ratio of 1.92 and a debt-to-equity ratio of 0.02.

Dr. Reddy’s Laboratories (NYSE:RDY) last announced its earnings results on Thursday, January 23rd. The company reported $0.20 earnings per share for the quarter, topping analysts’ consensus estimates of $0.19 by $0.01. Dr. Reddy’s Laboratories had a return on equity of 17.87% and a net margin of 17.25%. On average, equities analysts anticipate that Dr. Reddy’s Laboratories Limited will post 0.8 EPS for the current year.

About Dr. Reddy’s Laboratories

Dr. Reddy’s Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company’s Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.